{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:49:45Z","timestamp":1791085785032,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T00:00:00Z","timestamp":1397088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1038\/bjc.2014.169","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T23:02:09Z","timestamp":1397170929000},"page":"2489-2495","source":"Crossref","is-referenced-by-count":39,"title":["Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance"],"prefix":"10.1038","volume":"110","author":[{"given":"A","family":"Azimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Pernemalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Frostvik Stolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lehti\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Egyh\u00e1zi Brage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Hertzman Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,10]]},"reference":[{"issue":"2","key":"BFbjc2014169_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1158\/1078-0432.CCR-08-1916","volume":"15","author":"CK Augustine","year":"2009","unstructured":"Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, Nevins JR, Ali-Osman F, Tyler DS (2009) Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 15 (2): 502\u2013510.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014169_CR2","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635\u20133648.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014169_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3322\/canjclin.54.3.131","volume":"54","author":"A Balch","year":"2004","unstructured":"Balch A, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2004) An evidence-basedstaging system for cutaneous melanoma. CA Cancer J Clin 54: 131\u2013149, (quiz 182\u2013184).","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"BFbjc2014169_CR4","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.ejca.2010.04.023","volume":"46","author":"C Busch","year":"2010","unstructured":"Busch C, Geisler J, Lillehaug JR, L\u00f8nning PE (2010) MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Eur J Cancer 46 (11): 2127\u20132133.","journal-title":"Eur J Cancer"},{"issue":"9","key":"BFbjc2014169_CR5","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0929-6646(10)60103-9","volume":"109","author":"R Cao","year":"2010","unstructured":"Cao R, Yan B, Yang H, Zu X, Wen G, Zhong J (2010) Effect of human S100A13 gene silencing on FGF-1 transportation in human endothelial cells. J Formos Med Assoc 109 (9): 632\u2013640.","journal-title":"J Formos Med Assoc"},{"key":"BFbjc2014169_CR6","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507\u20132516.","journal-title":"N Engl J Med"},{"key":"BFbjc2014169_CR7","doi-asserted-by":"publisher","first-page":"9903","DOI":"10.1073\/pnas.0600213103","volume":"103","author":"KG Chen","year":"2006","unstructured":"Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F et al (2006) Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci USA 103: 9903\u20139907.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"BFbjc2014169_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/156652413804486214","volume":"13","author":"R Donato","year":"2013","unstructured":"Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL (2013) Functions of S100 proteins. Curr Mol Med 13 (1): 24\u201357.","journal-title":"Curr Mol Med"},{"key":"BFbjc2014169_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ijc.27616","volume":"132","author":"F Erdmann","year":"2013","unstructured":"Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart EW, Bray F (2013) International trends in the incidence of malignant melanoma 1953-2008\u2014are recent generations at higher or lower risk? Int J Cancer 132: 385\u2013400.","journal-title":"Int J Cancer"},{"issue":"3","key":"BFbjc2014169_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00216-004-2783-y","volume":"380","author":"L Eriksson","year":"2004","unstructured":"Eriksson L, Antti H, Gottfries J, Holmes E, Johansson E, Lindgren F, Long I, Lundstedt T, Trygg J, Wold S (2004) Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem 380 (3): 419\u2013429.","journal-title":"Anal Bioanal Chem"},{"key":"BFbjc2014169_CR11","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J (2012a) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694\u20131703.","journal-title":"N Engl J Med"},{"key":"BFbjc2014169_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D METRIC Study Group (2012b) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107\u2013114.","journal-title":"N Engl J Med"},{"key":"BFbjc2014169_CR13","first-page":"72","volume":"5","author":"EA Gashenko","year":"2013","unstructured":"Gashenko EA, Lebedeva VA, Brak IV, Tsykalenko EA, Vinokurova GV, Korolenko TA (2013) Evaluation of serum procathepsin B, cystatin B and cystatin C as possible biomarkers of ovarian cancer. Int J Circumpolar Health 5: 72.","journal-title":"Int J Circumpolar Health"},{"key":"BFbjc2014169_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cncr.22427","volume":"109","author":"HJ Gogas","year":"2007","unstructured":"Gogas HJ, Kirkwood JM, Sondak VK (2007) Chemotherapy for metastatic melanoma: time for a change? Cancer 109: 455\u2013464.","journal-title":"Cancer"},{"issue":"7","key":"BFbjc2014169_CR15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jprot.2011.04.013","volume":"74","author":"WM Hardesty","year":"2011","unstructured":"Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM (2011) Protein signatures for survival and recurrence in metastatic melanoma. J Proteomics 74 (7): 1002\u20131014.","journal-title":"J Proteomics"},{"key":"BFbjc2014169_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Mart\u00edn-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358\u2013365.","journal-title":"Lancet"},{"issue":"suppl 5","key":"BFbjc2014169_CR17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0923-7534(20)31340-5","volume":"23","author":"C Hertzman Johansson","year":"2012","unstructured":"Hertzman Johansson C, Azimi A, Pernemalm M, Pawitan Y, Frostvik Stolt M, Lazar V, Lundeberg J, Lehti\u00f6 J, Egyh\u00e1zi S, Hansson. J (2012) Proteomics and gene expression profiling of melanoma chemotherapy response in tumors. WIN 2012 Symposium, Paris, June 28-29, 2012. Ann Oncol 23 (suppl 5): 27.","journal-title":"Ann Oncol"},{"key":"BFbjc2014169_CR18","doi-asserted-by":"crossref","unstructured":"Hertzman Johansson C, Azimi A, Frostvik Stolt M, Shojaee S, Wiberg H, Grafstr\u00f6m E, Hansson J, Egyh\u00e1zi Brage S (2013) Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines. Melanoma Res e-pub ahead of print 5 August 2013.","DOI":"10.1097\/CMR.0b013e328362f9cd"},{"key":"BFbjc2014169_CR19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/1097-0142(19840315)53:6<1299::AID-CNCR2820530613>3.0.CO;2-4","volume":"53","author":"GJ Hill 2nd","year":"1984","unstructured":"Hill GJ 2nd, Krementz ET, Hill HZ (1984) Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131 and 7131A). Cancer 53: 1299\u20131305.","journal-title":"Cancer"},{"key":"BFbjc2014169_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb\u00e9 C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711\u2013723.","journal-title":"N Engl J Med"},{"issue":"6","key":"BFbjc2014169_CR21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1755-148X.2008.00505.x","volume":"21","author":"KS Hoek","year":"2008","unstructured":"Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir K, Schepsky A, Dummer R, Steingrimsson E (2008) Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res 21 (6): 665\u2013676.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"BFbjc2014169_CR22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.bbrc.2004.02.135","volume":"316","author":"HL Hsieh","year":"2004","unstructured":"Hsieh HL, Sch\u00e4fer BW, Weigle B, Heizmann CW (2004) S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. Biochem Biophys Res Commun 316 (3): 949\u2013959.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFbjc2014169_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1634\/theoncologist.2009-0237","volume":"15","author":"C Kim","year":"2010","unstructured":"Kim C, Lee CW, Kovacic L, Shah A, Klasa R, Savage KJ (2010) Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist 15: 765\u2013771.","journal-title":"Oncologist"},{"issue":"2","key":"BFbjc2014169_CR24","first-page":"505","volume":"6","author":"J Kos","year":"2000","unstructured":"Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Br\u00fcnner N (2000) Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res 6 (2): 505\u2013511.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"BFbjc2014169_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11060-006-9189-y","volume":"80","author":"M Landriscina","year":"2006","unstructured":"Landriscina M, Schinzari G, Di Leonardo G, Quirino M, Cassano A, D'Argento E, Lauriola L, Scerrati M, Prudovsky I, Barone C (2006) S100A13, a new marker of angiogenesis in human astrocytic gliomas. J Neurooncol 80 (3): 251\u2013259.","journal-title":"J Neurooncol"},{"issue":"8","key":"BFbjc2014169_CR26","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/sj.bjc.6601270","volume":"89","author":"S Ma","year":"2003","unstructured":"Ma S, Egyh\u00e1zi S, Ueno T, Lindholm C, Kreklau EL, Stierner U, Ringborg U, Hansson J (2003) O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 89 (8): 1517\u20131523.","journal-title":"Br J Cancer"},{"issue":"6","key":"BFbjc2014169_CR27","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/modpathol.2010.54","volume":"23","author":"D Massi","year":"2010","unstructured":"Massi D, Landriscina M, Piscazzi A, Cosci E, Kirov A, Paglierani M, Di Serio C, Mourmouras V, Fumagalli S, Biagioli M, Prudovsky I, Miracco C, Santucci M, Marchionni N, Tarantini F (2010) S100A13 is a new angiogenic marker in human melanoma. Mod Pathol 23 (6): 804\u2013813.","journal-title":"Mod Pathol"},{"issue":"15","key":"BFbjc2014169_CR28","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1016\/j.ejca.2013.06.027","volume":"49","author":"AM Menzies","year":"2013","unstructured":"Menzies AM, Long GV (2013) Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. Eur J Cancer 49 (15): 3229\u20133241.","journal-title":"Eur J Cancer"},{"key":"BFbjc2014169_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18: 158\u2013166.","journal-title":"J Clin Oncol"},{"issue":"16","key":"BFbjc2014169_CR30","doi-asserted-by":"publisher","first-page":"14608","DOI":"10.1074\/jbc.M110.201954","volume":"286","author":"SK Mohan","year":"2011","unstructured":"Mohan SK, Yu C . The IL1alpha-S100A13 heterotetrameric complex structure: a component in the non-classical pathway for interleukin 1alpha secretion (2011) J Biol Chem 286 (16): 14608\u201314617.","journal-title":"J Biol Chem"},{"issue":"10","key":"BFbjc2014169_CR31","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","volume":"47","author":"PM Patel","year":"2011","unstructured":"Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, Conry R, Thompson JA, Hwu WJ, Engelen K, Agarwala SS, Keilholz U, Eggermont AM, Spatz A EORTC Melanoma Group (2011) Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47 (10): 1476\u20131483.","journal-title":"Eur J Cancer"},{"issue":"7","key":"BFbjc2014169_CR32","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1021\/pr400124w","volume":"12","author":"V Paulitschke","year":"2013","unstructured":"Paulitschke V, Haudek-Prinz V, Griss J, Berger W, Mohr T, Pehamberger H, Kunstfeld R, Gerner C (2013) Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells. J Proteome Res 12 (7): 3264\u20133276.","journal-title":"J Proteome Res"},{"issue":"1","key":"BFbjc2014169_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejca.2007.10.017","volume":"44","author":"A Pierce","year":"2008","unstructured":"Pierce A, Barron N, Linehan R, Ryan E, O'Driscoll L, Daly C, Clynes M (2008) Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines. Eur J Cancer 44 (1): 151\u2013159.","journal-title":"Eur J Cancer"},{"issue":"17","key":"BFbjc2014169_CR34","doi-asserted-by":"publisher","first-page":"7674","DOI":"10.1158\/0008-5472.CAN-04-3016","volume":"65","author":"SA Schwartz","year":"2005","unstructured":"Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, Johnson MD, Caprioli RM (2005) Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 65 (17): 7674\u20137681.","journal-title":"Cancer Res"},{"issue":"14","key":"BFbjc2014169_CR35","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1002\/elps.200305456","volume":"24","author":"P Sinha","year":"2003","unstructured":"Sinha P, Poland J, Kohl S, Schn\u00f6lzer M, Helmbach H, H\u00fctter G, Lage H, Schadendorf D (2003) Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis 24 (14): 2386\u20132404.","journal-title":"Electrophoresis"},{"issue":"20","key":"BFbjc2014169_CR36","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/onc.2010.612","volume":"30","author":"T Strub","year":"2011","unstructured":"Strub T, Giuliano S, Ye T, Bonet C, Keime C, Kobi D, Le Gras S, Cormont M, Ballotti R, Bertolotto C, Davidson I (2011) Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene 30 (20): 2319\u20132332.","journal-title":"Oncogene"},{"issue":"1","key":"BFbjc2014169_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2174\/157015912799362733","volume":"10","author":"K Suk","year":"2012","unstructured":"Suk K (2012) Proteomic analysis of glioma chemoresistance. Curr Neuropharmacol 10 (1): 72\u201379.","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"BFbjc2014169_CR38","first-page":"647","volume":"16","author":"B Werle","year":"2006","unstructured":"Werle B, Schanzenb\u00e4cher U, Lah TT, Ebert E, J\u00fclke B, Ebert W, Fiehn W, Kayser K, Spiess E, Abrahamson M, Kos J (2006) Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis. Oncol Rep 16 (4): 647\u2013655.","journal-title":"Oncol Rep"},{"key":"BFbjc2014169_CR39","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/0008-5472.CAN-08-0506","volume":"69","author":"T Xie","year":"2009","unstructured":"Xie T, Nguyen T, Hupe M, Wei ML (2009) Multidrug resistance decreases with mutations of melanosomal regulatory genes. Cancer Res 69: 992\u2013999.","journal-title":"Cancer Res"},{"key":"BFbjc2014169_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1874467211205010102","volume":"5","author":"J Zhang","year":"2012","unstructured":"Zhang J, Stevens MFG, Bradshaw TD (2012) Temozolomide: Mechanisms of action, repair and resistance. Curr Mol Pharmacol 5: 102\u2013114.","journal-title":"Curr Mol Pharmacol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2014169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014169","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:22:31Z","timestamp":1684416151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2014169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["BFbjc2014169"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2014.169","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,10]]}}}